News & Updates
Filter by Specialty:
Rapid childhood growth rate tied to elevated risk of islet autoimmunity, T1D development
Children who grow in height fast appears to have a higher risk of islet autoimmunity (IAA) and rapid progression to type 1 diabetes (T1D), a study has found.
Rapid childhood growth rate tied to elevated risk of islet autoimmunity, T1D development
21 Jun 2022Normal weight obesity in adolescents tied to cardiometabolic risk
Adolescents with normal weight obesity (NMO) may present with several cardiometabolic risk factors, putting them at greater risk of developing vascular events or diabetes, suggests a recent study.
Normal weight obesity in adolescents tied to cardiometabolic risk
21 Jun 2022Insulin resistance tied to atherogenic lipoprotein/lipid, cIMT in obese youths
Insulin resistance in young people with obesity is positively associated with an atherogenic lipoprotein/lipid profile and carotid intima-media thickness (cIMT), regardless of their glucose tolerance status, suggests a study.
Insulin resistance tied to atherogenic lipoprotein/lipid, cIMT in obese youths
20 Jun 2022Dulaglutide: A new horizon for T2D treatment in kids
A once-weekly subcutaneous dose of the GLP-1* receptor agonist dulaglutide successfully controlled glycaemic levels in youths with type 2 diabetes (T2D) being treated with lifestyle modification with or without metformin or insulin, results of the multinational, phase III AWARD-PEDS** study showed.
Dulaglutide: A new horizon for T2D treatment in kids
18 Jun 2022LDL-C properly managed in older T2DM patients
Regardless of the use of medication, levels of low-density lipoprotein cholesterol (LDL-C) appear to be appropriately managed in older type 2 diabetes mellitus (T2DM) patients, contributing to the prevention of coronary artery disease (CAD), a recent study has found.
LDL-C properly managed in older T2DM patients
18 Jun 2022Concomitant insulin may counter renoprotective effects of SGLT2is in T2D patients with CKD
Renal composite outcomes (RCO) appear to be less favourable among type 2 diabetes (T2D) patients with chronic kidney disease (CKD) treated with insulin and sodium-glucose cotransporter 2 inhibitors (SGLT2i), a recent Japan study has found.